George Church talks about his disappointment with the Human Genome Project, the blistering price/performance improvements in both DNA synthesis and sequencing, and CRISPR’s strength and weaknesses, in addition to the improvements he hopes to see in its successors.
Disruptive science can have a significant impact outside of our own domains of research and into our personal lives. Keeping abreast of these developments can help prepare and inspire.
A new technique, dubbed intron seqFISH enables scientists to image 10,421 genes at once within individual cells.
Leading cancer and gene therapy scientist, Inder Verma, has resigned from the Salk Insitute for Biological Studies in San Diego, California.
The deal gives Editas Medicine an exclusive ‘first’ to negotiate for licenses to genome-editing inventions that rise from the sponsored research.
Figuring out what causes diseases like autism, schizophrenia and depression is tricky. Now Stanford University researchers are turning blood into brain cells to study these diseases in a dish.
Dying cells generally have two options: go quietly, or go out with a bang. The latter, while more conspicuous, is also mechanistically more mysterious. Now, scientists have pinpointed what they believe is the molecular “code” that unleashes this more violent variety of cell death.
Non-profit Bill & Melinda Gates Medical Research Institute (MRI) has officially been launched, creating a new vision for drug development with a clear focus on the millions of people that die annually from contracting malaria, tuberculosis and diarrheal diseases.
A research team has identified the essential role of a structural protein in the silencing of the inactive X chromosome, a process that prevents both copies of the same gene from being expressed in female mammals, which carry two copies of the X chromosome.
FDA commissioner, Scott Gottlieb said that he expects the FDA to approve 40 gene therapies by 2022 in a fireside chat at the 2018 BIO International Convention.
Probably not. But there is an increasing demand for people with data and computing skills, and the life sciences sector in California may be losing the battle with Silicon Valley for those people.
Scientists now have easy access to the full power of CRISPR, without any learning curve, thanks to Synthego’s Engineered Cells Portfolio.
Researchers have synthesized the first artificial human prion, a dramatic development in efforts to combat a devastating form of brain disease that has so far eluded treatment and a cure.